This ASCO Breast Cancer conference is in early Jun
Post# of 148321
(Total Views: 642)
Posted On: 05/11/2022 10:49:13 PM
This ASCO Breast Cancer conference is in early June, ~3 weeks away.
If more than 14 of the 28 patients remain alive by then, the overall survivability of mTNBC patients who use leronlimab becomes 19 months. It was 12 months in November 2021 and now we will have 6 or 7 months more giving us an OS of 18 or 19 months. Gilead's Trodelvy OS is only 12 months and that is its best after trying for at least 3 years. The best it could do is only 1 year of OS while we are just getting started and we will be at 1.5 years minimum. We will be like the energizer bunny, keeps going and going and going. Or like the Timex which takes a licking and keeps on ticking. No, we are like Coke, We are the real thing.
My guess, we have a minimum of 20 patients still alive, if not 24.
If more than 14 of the 28 patients remain alive by then, the overall survivability of mTNBC patients who use leronlimab becomes 19 months. It was 12 months in November 2021 and now we will have 6 or 7 months more giving us an OS of 18 or 19 months. Gilead's Trodelvy OS is only 12 months and that is its best after trying for at least 3 years. The best it could do is only 1 year of OS while we are just getting started and we will be at 1.5 years minimum. We will be like the energizer bunny, keeps going and going and going. Or like the Timex which takes a licking and keeps on ticking. No, we are like Coke, We are the real thing.
My guess, we have a minimum of 20 patients still alive, if not 24.
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼